Enlivex Therapeutics (ENLV) Stock Analysis

What Enlivex Therapeutics does

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Key metrics

ETFs linked to ENLV

Broad-market and Healthcare sector ETFs an investor holding Enlivex Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ENLV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Enlivex Therapeutics?

Enlivex Therapeutics trades under the ticker ENLV on NASDAQ.

Which exchange is ENLV listed on?

ENLV is listed on NASDAQ.

What sector does Enlivex Therapeutics operate in?

Enlivex Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ENLV in a portfolio?

PortView shows ENLV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.